SCHEMBL30153130

SCHEMBL30153130

CCNCc1cc2nc(-c3cc(-c4ccc(F)cc4-c4nncn4C)cc(C4CC4)n3)oc2c(F)c1F

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24820424 1.00 CBLB (0.34) CBLB
SCHEMBL24820423 0.93 CBLB (0.35) CBLB
SCHEMBL30152756 0.93 CBLB (0.35) CBLB
SCHEMBL29189928 0.92 CBLB (0.34) CBLB
SCHEMBL30152656 0.92 CBLB (0.34) CBLB
SCHEMBL24820589 0.91 CBLB (0.33) CBLB
SCHEMBL24819915 0.91 CBLB (0.34) CBLB
SCHEMBL30152982 0.91 CBLB (0.34) CBLB
SCHEMBL30153068 0.91 CBLB (0.33) CBLB
SCHEMBL24819058 0.89 CBLB (0.32) CBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. 2025-05-22 — — US disclosed
EP-4359381-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-05-01 — — EP disclosed
WO-2022272248-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC CBLB 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback